Skip to main
BNTX
BNTX logo

BioNTech SE (BNTX) Stock Forecast & Price Target

BioNTech SE (BNTX) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 27%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

BioNTech's financial position is solid, with approximately €16.7 billion in cash, cash equivalents, marketable securities, and trade receivables as of the end of Q3 2025, providing a robust foundation for its continued growth and investment in pharmaceutical research. The incremental positive developments surrounding the global Phase 3 DYNASTY-Breast02 trial for candidate BNT323 signal potential advancements in its oncology pipeline, which is varied and consists of multiple innovative therapies. Additionally, the company’s continued innovation in its Covid-19 vaccine, demonstrated by improved immune responses against multiple SARS-CoV-2 sublineages in preclinical models, underscores BioNTech's commitment to addressing emerging infectious diseases, further enhancing its market position.

Bears say

The financial outlook for BioNTech exhibits several concerns that contribute to a negative assessment of its stock. With a projected full-year net loss per diluted share of €3.99 and a recorded net loss of €0.12 per diluted share for 3Q25, the company faces significant financial challenges. Furthermore, risks associated with potential negative data from multiple drug candidates, slower-than-expected market uptake, regulatory hurdles, and commercial risks impact investor confidence, particularly amidst the evolving COVID-19 vaccine landscape.

BioNTech SE (BNTX) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 27% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioNTech SE (BNTX) Forecast

Analysts have given BioNTech SE (BNTX) a Buy based on their latest research and market trends.

According to 11 analysts, BioNTech SE (BNTX) has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $137.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $137.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioNTech SE (BNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.